FRANKLIN LAKES, N.J., Feb. 2, 2018 /PRNewswire/ -- As previously disclosed, on December 29, 2017,BD (Becton, Dickinson and Company) (NYSE: BDX) completed the acquisition of C. R. Bard, Inc. ("Bard"). In relation to the acquisition, BD has provided supplemental, unaudited historical financial information on the Investor page of its website at www.bd.com/investors.
About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
Contact:Kristen Cardillo, Corporate Communications 201-847-5657Monique N. Dolecki, Investor Relations 201-847-5378
View original content:http://www.prnewswire.com/news-releases/comparable-historical-revenue-schedules-inclusive-of-c-r-bard-posted-to-bd-website-300592977.html
SOURCE BD (Becton, Dickinson and Company)
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All